Quality of life and mood assessment in conservatively treated cavernous malformation-related epilepsy

Laurèl Rauschenbach¹ | Pauline Bartsch¹ | Alejandro N. Santos¹ | Annika Lenkeit¹ | Marvin Darkwah Oppong¹ | Karsten H. Wrede¹ | Ramazan Jabbarli¹ | Witold X. Chmielewski¹ | Börge Schmidt² | Carlos M. Quesada³ | Michael Forsting⁴ | Ulrich Sure¹ | Philipp Dammann¹

¹Department of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany
²Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, Essen, Germany
³Department of Neurology, Division of Epilepsy, University Hospital Essen, Essen, Germany
⁴Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany

Abstract

Background: To estimate the quality of life, anxiety, depression, and illness perception in patients with medically treated cerebral cavernous malformation (CCM) and associated epilepsy.

Methods: Nonsurgically treated patients with CCM-related epilepsy (CRE) were included. Demographic, radiographic, and clinical features were assessed. All participants received established questionnaires (short-form 36 health survey, SF-36; hospital anxiety and depression score, HADS-A/D; visual analogue scale score, VAS) assessing the functional and psychosocial burden of disease. To some extent, calculated values were compared with reference values from population-based studies. Test results were related to seizure control.

Results: A total of 37 patients were included. Mean age was 45.8 ± 14.4 years, and 54.1% were female. Diagnosis of CRE was significantly associated with attenuated quality of life and increased level of anxiety, affecting physical and psychosocial dimensions. The assessment of illness perception identified considerable burden. HADS was significantly associated with VAS and SF-36 component scores. Efficacy of antiepileptic medication had no restoring impact on quality of life, anxiety, depression, or illness perception.

Conclusions: CRE negatively influences quality of life and mood, independent of seizure control due to antiepileptic medication. Screening for functional and psychosocial deficits in clinical practice might be useful for assessing individual burden and allocating surgical or drug treatment.

Keywords: anxiety, cerebral cavernous malformation, depression, epilepsy, quality of life
1 | INTRODUCTION

Cerebral cavernous malformations (CCMs) are the second most common type of neurovascular malformation in the central nervous system, representing between 10% and 15% of all vascular malformations (Washington et al., 2010). Although there is low blood pressure and slow blood flow within these lesions, CCMs carry considerable risk of intracerebral hemorrhage (Taslimi et al., 2016). Irrespective of bleeding occurrence, CCMs can implicate headaches, seizures, or focal neurological deficits (Horne et al., 2016). CCM-related epilepsy (CRE) is a common phenomenon in CCM, with an incidence of ≈30% (Al-Shahi Salman et al., 2012; Dammann, Wrede, et al., 2017; Horne et al., 2016).

Even though the underlying mechanisms are poorly understood, few studies identified associations between CRE and CCM multiplicity, cortical involvement, or CCM-related hemosiderin deposition (Dammann, Schaller, et al., 2017; He et al., 2017; Menzler et al., 2010; Moultrie et al., 2014). Notably, CCM treatment is still subject to debate. Evidence-based treatment guidelines are scarce and decision-making is often limited to clinical experience (Dammann et al., 2021; Rosenow et al., 2013). Although lesion removal in CRE patients seems justified in selected cases, brain surgery remains a delicate procedure, and noninvasive treatment approaches must be considered, particularly in patients who have minor or no functional impairments (Dammann, Wrede, et al., 2017).

Epileptic seizures can have a considerable impact on health-related quality of life (HRQOL) (Mahrer-Imhof et al., 2013), and treatment pathways should take into account not only neurological but also psychosocial burden. While the vast majority of CCM studies focus on different treatment strategies and risk factors leading to hemorrhage (Al-Shahi Salman et al., 2016), literature reporting on HRQOL is rare (Bicalho et al., 2017; Rinkel et al., 2019). Recently published data highlight the impact of CCM disease on self-reported quality of life but HRQOL and mood have never been studied exclusively in medically treated CRE patients (Herten et al., 2021).

In this study, conservatively treated patients were screened for disease-related functional and psychosocial burden. Moreover, the results were compared to the average population and related to seizure control.

2 | METHODS

2.1 | Study design

A prospective cross-sectional study was performed of all patients who were admitted to our specialized outpatient clinic for CCM disease between November 2017 and January 2020. During consultation, all patients were given general information about diagnosis, treatment strategies, and prognosis. Participants needed to fulfill the inclusion criteria mentioned below. Informed consent was obtained from all participants. The study was conducted in accordance with the principles expressed in the Declaration of Helsinki. A local ethics committee approved all procedures (Review Board Identification Number: 15-6636-BO). The trial was performed in accordance with Strengthening the Reporting of Observational Studies in Epidemiology protocol. Parts of the data were published previously in a study, investigating HRQOL in patients with untreated cavernous malformations of the central nervous system (Herten et al., 2021).

2.2 | Inclusion and exclusion criteria

We included patients aged between 18 and 80 years and diagnosed with CRE according to the definition by Rosenow et al. (2013). CCM diagnosis was based on magnetic resonance imaging (MRI) including T1, T2, contrast-enhanced, and susceptibility-weighted or T2*-weighted gradient echo imaging. Patients were treated conservatively. Individuals who received invasive treatment and were hospitalized within 3 months prior to study were excluded. Patients required sufficient knowledge of the German language to cope with the testing.

2.3 | Data collection

Clinical data and imaging data were assessed prospectively and in accordance with CCM reporting standards (Al-Shahi Salman et al., 2008). An experienced neuroradiologist evaluated imaging data. The following clinical and radiological features were assessed: age, sex, number of CCMs, lesion localization, occurrence of CCM-related hemorrhage (Taslimi et al., 2016), physical or psychiatric comorbidities, epilepsy semiology, number of seizures, antiepileptic medication, time between first and last CCM-related seizure, time between first CCM-related seizure and neuropsychological testing, and time between last CCM-related seizure and neuropsychological testing. The degree of disability was determined using the modified Rankin Scale (mRS). Outcome was considered favorable if the patient had a mRS less than or equal to 2 and unfavorable if the mRS was greater than 2. HRQOL was assessed in a standardized interview using the German version of the 36-item short form health survey (SF-36). Depression and anxiety were addressed using the hospital anxiety and depression rating scale (HADS-A/D). Moreover, subjective perception of disease and burden of CRE were evaluated using a visual analog scale (VAS). Testing was conducted by one interviewer to avoid interobserver effects.

The SF-36 questionnaire addresses two main domains comprised of 8 subdomains with 36 questions items: physical functioning (PF), social functioning (SF), role limitations due to physical problems (RP), role limitations due to emotional problems (RE, three items), mental health (MH, 5 items), vitality (VT, four items), bodily pain (BP, two items), and general health perceptions (GH, five items). Additionally, we determined two overall component scores: physical health component score (PCS) and mental health component score (MCS). For each subdomain, an overall score was assessed (0 = worst subjective health state; 100 = best subjective health state). The HADS-A/D scale consists of a questionnaire containing 14 questions, with 7 referring to anxiety and seven referring to depression. With the VAS score, the individual patient burden was determined. This psychometric scale ranges from 1 (no burden) to 10 (maximum burden).
SF-36 and HADS-A/D scores were compared with data from German reference population studies. For SF-36 testing, the reference data were provided by the population-based Heinz Nixdorf Recall Study and the associated MultiGeneration study (Schmermund et al., 2002). Participants were randomly selected from three German cities (i.e., Essen, Bochum, and Mülheim a.d. Ruhr). Individual matching (1:3) was applied to ensure that CCM cases and population-based controls had the same distribution over strata defined by age (5-year groups) and sex. For HADS-A/D testing, reference values were derived from a large population-based investigation (Hinz & Brähler, 2011).

### 2.4 Statistical analyses

Statistical analysis was performed using SPSS version 22 (IBM Corp.). Data were tested for normal distribution by performing a Shapiro-Wilk test. For interval-scaled data, mean values, and standard deviation were calculated, while absolute numbers and valid percent were used for nominal data. The unpaired t-test (normally distributed data) or the Mann-Whitney U test (non-normally distributed data) were used to compare continuous variables. Effect size was reported using Cohen’s d, and values were categorized according to an established classification system: small effect (>0.2), medium effect (>0.5), and large effect (>0.8) (Rice & Harris, 2005). The degree of correlation was calculated using the Spearman’s rank correlation test. For linear regression analyses, $R^2$ values were determined. All tests were two tailed, and $p$-values < .05 were defined as significant.

### 3 RESULTS

#### 3.1 Patient demographics

A total of 37 patients were included in this study. Mean age was $45.8 \pm 14.4$ years, and 20 participants (54.1%) were female. Six patients (16.2%) exhibited multiple CCMs. Lesions were most commonly located in the temporal lobe. CCM-related hemorrhage was a common phenomenon and affected 18 (48.6%) individuals. The majority of patients (97.3%) were in good clinical condition (mRS $\leq 2$). Fifteen participants (40.4%) had diseases that were not related to CCM disease, including 13 patients (35.1%) suffering from physical and two patients (5.4%) from psychiatric comorbidities. Detailed information on demographic, anatomic, and clinical data is provided in Table 1.

#### 3.2 Cavernoma-related epilepsy

At the time of testing, all participants had experienced at least one epileptic seizure. Most patients (64.9%) had a history of one single seizure, but several individuals (35.1%) were admitted with a history of recurrent seizures. In the majority of cases (75.7%), anticonvulsant treatment was administered at the time of testing, mainly consisting of one single drug. According to treatment guidelines, the most com-

| Characteristic | Frequency |
|---------------|-----------|
| Total number of patients with CRE, n | 37 |
| Age, years, mean ± SD | 45.8 ± 14.4 |
| Sex, n (%) | |
| Male | 17 (45.9) |
| Female | 20 (54.1) |
| CCM number, n (%) | |
| Solitary (1 CCM) | 31 (83.8) |
| Multiple (≥2 CCM) | 6 (16.2) |
| CCM localization, n (%) | |
| Frontal lobe | 9 (24.3) |
| Parietal lobe | 5 (13.5) |
| Temporal lobe | 10 (27) |
| Occipital lobe | 3 (8.1) |
| Multiple lobes | 7 (18.9) |
| Subcortical | 3 (8.1) |
| CCM-related hemorrhage, n (%) | 18 (48.6) |
| mRS, n (%) | |
| 0 | 2 (5.4) |
| 1 | 31 (83.8) |
| 2 | 3 (8.1) |
| 3 | 1 (2.7) |
| Comorbidities, n (%) | |
| Physical comorbidities | 13 (35.1) |
| Psychiatric comorbidities | 2 (5.4) |
| CRE semiology, n (%) | |
| Focal epilepsy | 11 (29.7) |
| Generalized epilepsy | 23 (62.2) |
| Absence epilepsy | 3 (8.1) |
| No. of seizures, n (%) | |
| 1 CCM-related seizure | 24 (64.9) |
| ≥2 CCM-related seizures | 13 (35.1) |
| Antiepileptic treatment, n (%) | |
| No treatment | 9 (24.3) |
| Monotherapy (1 drug) | 22 (59.3) |
| Combination therapy (2 drugs) | 6 (16.2) |
| Antiepileptic medication, n (%) | |
| Carbamazepine | 1 (2.9) |
| Clonazepam | 1 (2.9) |
| Lacosamide | 1 (2.9) |
| Lamotrigine | 5 (14.7) |
| Levetiracetam | 19 (55.9) |
| Oxcarbazepine | 1 (2.9) |
| Pregabalin | 1 (2.9) |
| Valproate | 3 (8.8) |
| Zonisamide | 2 (5.9) |

(Continues)
mon medication was levetiracetam (55.9%) and lamotrigen (14.7%). Patients with multiple seizures featured a relatively low seizure frequency. At admission, these patients had a history of $33.2 \pm 88.7$ months between first and last seizure. In the total cohort, participants were interviewed $60.1 \pm 101.5$ months after their first seizure and $28.9 \pm 59.6$ months after their last seizure. Detailed information on clinical data is provided in Table 1.

### 3.3 Health-related quality of life

HRQOL was assessed using the German version of the SF-36. The results for CRE patients and for the age- and gender-matched German reference population are presented in Figure 1. Compared to the reference population, CCM patients with CRE had decreased scores in all domains and component scores. In 18 patients (48.6%), the PCS was 2 points lower than the mean score of the average population. Thirty-three participants (89.2%) experienced a similar decrease in the MCS. Notably, a two-point decrease is regarded as relevant (McHorney & Ware, 1995; Ware et al., 1995). Statistical testing demonstrated significantly impaired scores in overall mental health score and in six additional subdomains ($p < .001$). Patients experienced limitations in usual role activities due to physical impairment (RP, $p = .0001$), attenuated general health (GH, $p = .0001$), decreased vitality (VT, $p = .0001$), limitations in social activities because of physical or emotional problems (SF, $p = .0001$), limitations in usual role activities due to emotional problems (RE, $p = .0001$) and worsened mental health (MH, $p = .0001$). Detailed analyses are provided in Table 2. Further investigation revealed differences in physical health component scores of patients with single ($52.0 \pm 7.7$) or multiple ($39.9 \pm 13.8$) CCM ($p = .004$), and differences in mental health component scores of patients with ($37.7 \pm 11.6$) or without ($44.9 \pm 8.9$) history of CCM-related hemorrhage ($p = .039$). Notably, there were no differences in test performance between male and female individuals.

### 3.4 Perception of illness, anxiety, and depression

Subjective perception of illness and burden of CRE were evaluated using a visual analog scale (VAS). The mean VAS score was $5.4 \pm 2.3$, indicating considerable symptom severity. Depression and anxiety were determined using the hospital anxiety and depression rating scale (HADS-A/D). In the CRE population, the mean HADS-A score was $7.9 \pm 4.4$ with 19 patients (51.4%) revealing a score more than or equal to 8, indicating relevant levels of anxiety. Compared to the average German population, values were considerably elevated (Hinz & Brähler, 2011). In contrast to anxiety, depression was less common in CRE patients. The mean HADS-D score was $5.6 \pm 4.2$ with 10 patients (27%) scoring 8 or more. These values were comparable to data derived from the German reference population (Hinz & Brähler, 2011). Detailed analyses are listed in Table 3. Notably, HADS-A, HADS-D, and VAS scores demonstrated a high degree of concordance among each other, indicating a correlation between the level of anxiety, depression, and perception of illness. Moreover, HADS-A and HADS-D were significantly associated with SF-36 component scores ($p \leq .003$), except for HADS-D and PCS. Detailed analyses are provided in Table S1. Subsequent analyses demonstrated differences in HADS-D scores of patients with
### TABLE 2  HRQOL testing in CRE and healthy populations

| SF-36 scale       | CRE population, mean ± SD | Reference population, mean ± SD | p<sup>a</sup> | Cohen’s d-value | Cohen’s d-effect<sup>b</sup> |
|-------------------|---------------------------|---------------------------------|--------------|----------------|-----------------|
| Physical health subdomains |                           |                                 |              |                |                 |
| PF                | 86.2 ± 19.6               | 91.6 ± 13.5                     | .0638        | 0.40           | +               |
| RP                | 67.6 ± 39.0               | 89.3 ± 25.4                     | .0001        | 0.85           | +++             |
| BP                | 75.9 ± 26.8               | 81.7 ± 22.3                     | .1954        | 0.26           | +               |
| GH                | 58.1 ± 21.8               | 72.5 ± 15.5                     | .0001        | 2.62           | +++             |
| VT                | 53.0 ± 20.4               | 67.1 ± 17.2                     | .0001        | 0.82           | +++             |
| Mental health subdomains |                           |                                 |              |                |                 |
| SF                | 67.9 ± 26.4               | 95.9 ± 10.8                     | .0001        | 2.59           | +++             |
| RE                | 65.7 ± 37.8               | 94.5 ± 22.9                     | .0001        | 1.26           | +++             |
| MH                | 61.4 ± 19.9               | 80.8 ± 13.8                     | .0001        | 1.42           | +++             |
| Component scores  |                           |                                 |              |                |                 |
| PCS               | 49.9 ± 9.9                | 52.8 ± 17.1                     | .3302        | 0.17           | +               |
| MCS               | 41.7 ± 10.8               | 55.2 ± 18.1                     | .0001        | 0.75           | ++              |
| Cohort matching   |                           |                                 |              |                |                 |
| Age (y), mean ± SD| 45.8 ± 14.4               | 45.8 ± 14.3                     | n/a          | n/a            | n/a             |
| Sex, n (%)        |                           |                                 |              |                |                 |
| Male              | 17 (45.9%)                | 51 (45.9%)                      | n/a          | n/a            | n/a             |
| Female            | 20 (54.1%)                | 60 (54.1%)                      |              |                |                 |

Note: Control-to-case ratio was 3:1. Significant p-values are in bold font. Abbreviations: BP, bodily pain; CRE, cavernoma-related epilepsy; GH, general health perception; MCS, mental health score; MH, Mental health; n/a, data not available; PCS, physical health score; PF, physical functioning; RE, role emotional; RP, role physical; SF, social functioning; VT, vitality.  
<sup>a</sup>Two-tailed Student’s t-test.  
<sup>b</sup>Interpretation of d according to Cohen: 0.2–0.5 small effect size (+), 0.5–0.8 medium effect size (++), >0.8 large effect size (+++).

### TABLE 3  Anxiety, depression, and subjective disease burden in CRE, CCM, and healthy populations

| Population      | Total Mean ± SD | <8 Mean ± SD | <8 n (%) | ≥8 Mean ± SD | ≥8 n (%) | HADS-A Total Mean ± SD | HADS-A <8 Mean ± SD | HADS-A <8 n (%) | HADS-A ≥8 Mean ± SD | HADS-A ≥8 n (%) | VAS Total Mean ± SD |
|-----------------|-----------------|--------------|----------|--------------|----------|------------------------|---------------------|------------------|---------------------|------------------|--------------------|
| CRE (n = 37)    | 7.9 ± 4.4       | 18 (48.6)    | 19 (51.4) | 5.6 ± 4.2    | 27 (73.0) | 10 (27.0)              | 5.4 ± 2.3           |                 |                     |                  |                    |
| Reference<sup>a</sup> (n = 4410) | Male 4.4 ± 3.3 | 1580 (81.9)  | 349 (18.1) | 4.8 ± 4.0    | 1468 (76.1) | 461 (23.9)              | n/a          |                 |                     |                  |                    |
|                 | Female 5.0 ± 3.6| 1905 (76.8)  | 576 (23.2) | 4.7 ± 3.9    | 1898 (76.5) | 583 (23.5)              | n/a          |                 |                     |                  |                    |

Abbreviations: CRE, cavernoma-related epilepsy; HADS, hospital anxiety and depression rating scale; n/a, not available; VAS, visual analogue scale.  
<sup>a</sup>Data on normative values of the German population according to Hinz & Brähler (2011).

(7.3 ± 4.9) or without (4.3 ± 3.2) history of CCM-related hemorrhage (p = .030). Again, there were no differences in test performance between male and female individuals.

### 3.5 Seizure control and seizure frequency

In the majority of cases, anticonvulsant medication resulted in sufficient seizure control, but some patients experienced pharmacoresistant epilepsy. We thus investigated the impact of seizure control on HRQOL, anxiety, depression, and perception of illness. Comparison between patients with good seizure control for more or less than 6, 12, or 24 months demonstrated no significant differences in SF-36 component scores (p > .05), HADS-A/D scores (p > .05), or VAS scores (p > .05), indicating minor impact of seizure control on quality of life, mood, and illness perception. Detailed values are presented in Figure 2a. Comparable with seizure control, frequency of experienced seizures had no influence on psychometric test results. Values for HRQOL, anxiety, depression, and perception of illness revealed no differences between patients who had experienced one or multiple seizures. The results are provided in Figure 2b.
FIGURE 2  Short Form-36 (SF-36) component score, hospital anxiety, and depression rating scale (HADS-A/D) score and visual analogue scale (VAS) score assessment in patients with seizure control for (A1) 6, (A2) 12, or (A3) 24 or in patients with (B) seizure multiplicity. Unpaired t-test was applied
Abbreviations: MCS, mental health score; ns, not significant; PCS, physical health score

3.6  Time since diagnosis

Due to the cross-sectional design of this study, patients were examined at different time points. Accordingly, time between first seizure and testing was referred to SF-36 component scores, HADS-A/D scores, and VAS scores. Data were visualized in scattered plots, and linear regression analyses revealed low R² values, indicating that none of the variance in test results was explained by the time between first seizure and testing. The results are illustrated in Figure 3.

4  DISCUSSION

In this cross-sectional study, we investigated the impact of medically treated CRE on quality of life and mood in a subset of patients who were not referred to surgery for various reasons. Patient-reported surveys were used to assess data, and results were related to seizure control.

Although seizure diseases are one of the most common presentations in CCM patients (Rosenow et al., 2013), functional and psychosocial burden is rarely discussed. Moreover, literature dealing with quality of life in CRE is exclusively limited to studies investigating the outcome after CCM removal (Dammann et al., 2017; Ruan et al., 2015; Van Gompel et al., 2010). Since treatment is often personalized, particularly in the case of CRE, patients and surgeons often face the difficult question of whether to opt for surgery or continue drug treatment (Dammann et al., 2021). Recently published data have highlighted the value of open and minimally invasive surgery for epileptogenic CCM lesions, including pediatric and adult patients (Dammann et al., 2017; Kapadia et al., 2021; Lee et al., 2017; Lin et al., 2018; Ozlen et al., 2021; Satzer et al., 2020; Schuss et al., 2020; Willie et al., 2019). Nevertheless, although early CCM removal is often feasible and effective, this topic is still a matter of debate, and high-quality evidence-based recommendations are missing (Awad & Polster, 2019; Zanello et al., 2019). In this scenario, clinical decision-making should not only rely on neurological assessment, due to the following reasoning.

Recently, Herten et al. (2021) tested quality of life in noninvasively treated patients and concluded that CCM strongly decreases HRQOL, even in the absence of functional impairment or neurological symptoms. Moreover, while numerous authors have described the negative impact of epileptic seizures on quality of life (Mahrer-Imhof et al., 2013; Villanueva et al., 2013), the impact of CRE in CCM patients has yet not been considered. To this end, we present a novel study investigating quality of life, anxiety, depression, and illness perception in medically treated CRE patients. In this trial, we were able to confirm the negative impact of epileptic seizures on quality of life and mood, even though the rating of burden showed pronounced interindividual differences.
FIGURE 3  Correlation between time since epilepsy onset and testing and Short Form-36 (SF-36) component scores, hospital anxiety, and depression rating scale (HADS-A/D) scores or visual analogue scale (VAS) scores. Linear regression analyses were applied. Abbreviations: MCS, mental health score; PCS, physical health score.

Furthermore, the calculated effect sizes ranged from small to large, underlining the high degree of heterogeneity in patient burden. Interestingly, neither the number of seizures experienced nor the length of time with sufficient seizure control had an influence on the patient-reported outcome. One might speculate that it is the diagnosis of CRE, but not the extent of neurological impairment, which is the most important contributing factor to the reduced quality of life and mood observed in our study.

In light of the promising seizure outcome after surgery for CRE (Dammann, Wrede, et al., 2017; Rosenow et al., 2013) and the increasing HRQOL after CCM removal in general (Cornelius et al., 2016; Dukatz et al., 2011), one might hypothesize that patients with strongly decreased quality of life could be eligible for lesionectomy. Patient-reported outcome parameters, for example, testing with SF-36 or HADS-A/D, could be used as benchmarks to assess the individual degree of functional and psychosocial deficits and to improve clinical management.

The shortcomings of this study are mainly related to the small sample size, the missing disease specificity of test instruments, and the reporting on data of a previously published patient cohort. Since symptomatic CCMs are often referred to surgery, the number of drug-treated CRE patients remains low. However, compared to large studies on CCM, our cohort exhibits typical characteristics with similar baseline data (Al-Shahi Salman et al., 2012; Horne et al., 2016). Thus, patients included in this study can be regarded as a representative sample of CCM patients, increasing the external validity of our reported results. Notably, SF-36, HADS-A/D, and VAS scores were not established to assess burden in CCM or CRE patients, limiting the specificity and sensitivity of testing. Nevertheless, disease-specific test instruments are missing, and SF-36, HADS-A/D, and VAS are established, validated, and convenient. These parameters might reflect disease burden beyond neurological impairment or seizures, making them useful for clinical application. Since parts of the data were published previously in a trial investigating HRQOL in patients with untreated...
cavernous malformations of the central nervous system, novelty of data is limited.

5 | CONCLUSION

Our report uncovers previously unrecognized functional and psychosocial deficits in medically treated CRE patients and highlights the clinical importance of psychometric testing. Seizure control had no restoring effect on outcome, underlining the value of surgical CCM removal irrespective of sufficient anticonvulsant treatment. A systematic analysis in a larger cohort is warranted.

ACKNOWLEDGMENT
The authors thank PD Dr. phil. Bernd-Otto Hütter for supporting neuropsychological assessment.

CONFLICT OF INTEREST
The authors have declared that no competing interest.

AUTHOR CONTRIBUTIONS
Laurèl Rauschenbach: responsible for designing the study protocol, summarized data, provided data, conducted data analysis, interpreted results, created figures and tables, wrote the manuscript, and reviewed the manuscript. Pauline Bartsch: summarized data, provided data, conducted data analysis, created figures and tables, and reviewed the manuscript. Alejandro N. Santos: summarized data, provided data, and reviewed the manuscript. Annika Lenkeit: summarized data, provided data, and reviewed the manuscript. Marvin Darkwah Oppong: summarized data, provided data, interpreted results, and reviewed the manuscript. Karsten H. Wrede: responsible for designing the study protocol and reviewed the manuscript. Ramazan Jabbarli: responsible for designing the study protocol and reviewed the manuscript. Witold X. Chmielewski: responsible for designing the study protocol, conducted data analysis, interpreted results, and reviewed the manuscript. Börge Schmidt: responsible for designing the study protocol, conducted data analysis, interpreted results, and reviewed the manuscript. Carlos M. Quesada: interpreted results and reviewed the manuscript. Michael Forsting: provided data, reviewed the manuscript. Ulrich Sure: responsible for designing the study protocol, provided data, interpreted results, and reviewed the manuscript. Philipp Dammann: responsible for designing the study protocol, summarized data, provided data, interpreted results, wrote the manuscript and reviewed the manuscript.

PEER REVIEW
The authors of this study thank the anonymous reviewers for their careful reading and improving this work. The peer review history for this article is available at https://publons.com/publon/10.1002/brb3.2595.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available in the supplementary material of this article and from the corresponding author upon reasonable request.

REFERENCES
Al-Shahi Salman, R., Berg, M. J., Morrison, L., & Awad, I. A. (2008). Hemorrhage from cavernous malformations of the brain: Definition and reporting standards. Angioma Alliance Scientific Advisory Board. Stroke; A Journal of Cerebral Circulation, 39, 3222–3230.
Al-Shahi Salman, R., Kitchin, N., Thomson, J., Ganesan, V., Mallucci, C., & Radatz, M. (2016). Top ten research priorities for brain and spine cavernous malformations. Lancet Neurology, 15, 354–355.
Al-Shahi Salman, R., Hall, J. M., Hone, M. A., Moultrie, F., Josephson, C. B., Bhattacharyya, J. J., Counsell, C. E., Murray, G. D., Papanastassiou, V., Ritchie, V., Roberts, R. C., Sellar, R. J., & Warlow, C. P. (2012). Untreated clinical course of cerebral cavernous malformations: A prospective, population-based cohort study. Lancet Neurology, 11, 217–224.
Awad, I. A., & Polster, S. P. (2019). Cavernous angiomas: Deconstructing a neurosurgical disease. Journal of Neurosurgery, 131, 1–13.
Bicalho, V. C., Bergmann, A., Domingues, F., Frossard, J. T., & de Souza, J. (2017). Cerebral cavernous malformations: patient-reported outcome validates conservative management. Cerebrovascular Diseases, 44, 313–319.
Cornellius, J. F., Kürten, K., Fischer, I., Hänggi, D., & Steiger, H. J. (2016). Quality of life after surgery for cerebral cavernoma: Brainstem versus non-brainstem location. World Neurosurgery, 95, 315–321.
Dammann, P., Abla, A. A., Al-Shahi Salman, R., Andrade-Barazarte, H., Benes, V., Cenzato, M., Connolly, E. S., Cornellius, J. F., Coulwood, W. T., Sola, R. G., Gomez-Paz, S., Hauck, E., Hernessiemi, J., Kivelev, J., Lanzino, G., MacDonald, R. L., Morcos, J. J., Ogilvy, C. S., ... Sure, U. (2021). Surgical treatment of brainstem cavernous malformations: An international Delphi consensus. Journal of Neurosurgery, 1–11.
Dammann, P., Schaller, C., & Sure, U. (2017). Should we resect peri-lesional hemosiderin deposits when performing lesionectomy in patients with cavernoma-related epilepsy (CRE)? Neurosurgical Review, 40, 39–43.
Dammann, P., Wrede, K., Jabbarli, R., Neuschulte, S., Menzler, K., Zhu, Y., Özkan, N., Müller, O., Forsting, M., Rosenow, F., & Sure, U. (2017). Outcome after conservative management or surgical treatment for new-onset epilepsy in cerebral cavernous malformation. Journal of Neurosurgery, 126, 1303–1311.
Dukatz, T., Sarnthein, J., Sitter, H., Bozinov, O., Benes, L., Sure, U., & Bertalanffy, H. (2011). Quality of life after brainstem cavernoma surgery in 71 patients. Neurosurgery, 69, 689–695.
He, K., Jiang, S., Song, J., Wu, Z., Chen, L., & Mao, Y. (2017). Long-term outcomes of surgical treatment in 181 patients with supratentorial cerebral cavernous malformation-associated epilepsy. World Neurosurgery, 108, 869–875.
Herten, A., Chen, B., Saban, D., Santos, A., Wrede, K., Jabbarli, R., Zhu, Y., Schmidt, B., Kleinschnitz, C., Forsting, M., Sure, U., & Dammann, P. (2021). Health-related quality of life in patients with untreated cavernous malformations of the central nervous system. European Journal of Neurology, 28, 491–499.
Hinz, A., & Brähler, E. (2011). Normative values for the hospital anxiety and depression scale (HADS) in the general German population. Journal of Psychosomatic Research, 71, 74–78.
Horne, M. A., Flemming, K. D., Su, I. C., Stapf, C., Jeon, J. P., Li, D., Maxwell, S. S., White, P., Christianson, T. J., Agid, R., Cho, W. S., Oh, C. W., Wu, Z., Zhang, J. T., Kim, J. E., Ter Brugge, K., Willinsky, R., Brown, R. D. Jr., Murray, G. D., & Al-Shahi Salman, R. (2016). Clinical course of untreated cerebral cavernous malformations: A meta-analysis of individual patient data. Lancet Neurology, 15, 166–173.
infarction and cardiac death in healthy middle-aged subjects: Rationale and design of the Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle. American Heart Journal, 144, 212–218.

Schuss, P., Marx, J., Borger, V., Brandecker, S., Güresir, Ä., Hadijathanasiou, A., Hamed, M., Schneider, M., Surges, R., Vatter, H., & Güresir, E. (2020). Cavernoma-related epilepsy in cavernous malformations located within the temporal lobe: Surgical management and seizure outcome. Neurosurgical Focus, 48, E6.

Taslimi, S., Modabbernia, A., Amin-Hanjani, S., Barker, F. G. 2nd, & MacDonald, R. L. (2016). Natural history of cavernous malformation: Systematic review and meta-analysis of 25 studies. Neurology, 86, 1984–1991.

Van Gompel, J. J., Marsh, W. R., Meyer, F. B., & Warrell, G. A. (2010). Patient-assessed satisfaction and outcome after microsurgical resection of cavernomas causing epilepsy. Neurosurgical Focus, 29, E16.

Villanueva, V., Girón, J. M., Martín, J., Hernández-Pastor, L. J., Lahuerta, J., Doz, M., Cuesta, M., & Lévy-Bachelot, L. (2013). Quality of life and economic impact of refractory epilepsy in Spain: The ESPERA study. Neurologia, 28, 195–204.

Ware, J. E. Jr., Kosinski, M., Bayliss, M. S., McHorney, C. A., Rogers, W. H., & Raczek, A. (1995). Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: Summary of results from the Medical Outcomes Study. Medical Care, 33, As264–As279.

Washington, C. W., McCoy, K. E., & Zipfel, G. J. (2010). Update on the natural history of cavernous malformations and factors predicting aggressive clinical presentation. Neurosurgical Focus, 29, E7.

Willie, J. T., Malcolm, J. G., Stern, M. A., Lowder, L. O., Neill, S. G., Cabaniss, B. T., Drane, D. L., & Gross, R. E. (2019). Safety and effectiveness of stereotactic laser ablation for epileptogenic cerebral cavernous malformations. Epilepsia, 60, 220–232.

Zanello, M., Meyer, B., Still, M., Goorden, J. R., Colle, H., Schichor, C., Bello, L., Wager, M., Smits, A., Rydenhag, B., Tate, M., Metelius, P., Hamer, P. W., Spena, G., Capelle, L., Mandonnet, E., Robles, S. G., Sarubbo, S., Martino González, J., ..., & Pallud, J. (2019). Surgical resection of cavernous angioma located within eloquent brain areas: International survey of the practical management among 19 specialized centers. Seizure: The Journal of the British Epilepsy Association, 69, 31–40.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Rauschenbach, L., Bartsch, P., Santos, A. N., Lenke, A., Darkwah Oppong, M., Wrede, K. H., Jabbarli, R., Chmielewski, W. X., Schmidt, B., Quesada, C. M., Forsting, M., Sure, U., & Dammann, P. (2022). Quality of life and mood assessment in conservatively treated cavernous malformation-related epilepsy. Brain and Behavior, 12, e2595. https://doi.org/10.1002/brb3.2595